We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.59B
1-Year Est. Return
234.06%
This Fund
S&P 500
This Quarter
Est. Return
+26.7%
1 Year Est. Return
+234.06%
3 Year Est. Return
+822.97%
5 Year Est. Return
+865.41%
10 Year Est. Return
+12,585.11%
AUM
$1.59B
AUM Growth
-$171M
(-9.7%)
Cap. Flow
-$411M
Cap. Flow
% of AUM
-25.91%
Top 10 Holdings %
Top 10 Hldgs %
89.82%
Holding
27
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACLX
Arcellx
ACLX
|
+$350M |
| 2 |
Celcuity
CELC
|
+$66.3M |
| 3 |
CVRx
CVRX
|
+$462K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.43% |
| 2 | Consumer Staples | 4.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Trevi Therapeutics
TRVI
$2.43B
| $247M | 15.53% |
13,222,228
| – | – |
|
|
MBX
2
MBX Biosciences
MBX
$2.96B
| $200M | 12.56% |
3,614,486
| – | – |
|
3
Monte Rosa Therapeutics
GLUE
$1.23B
| $186M | 11.72% |
7,692,298
| – | – |
|
|
4
Celcuity
CELC
$4.72B
| $179M | 11.27% |
1,710,561
-575,000
| -25% | -$66.3M |
|
|
SGP
5
SpyGlass Pharma
SGP
$970M
| $165M | 10.36% |
7,392,301
| – | – |
|
6
Savara
SVRA
$1.1B
| $151M | 9.49% |
24,471,264
| – | – |
|
|
ZBIO
7
Zenas BioPharma
ZBIO
$2.15B
| $102M | 6.43% |
4,023,219
| – | – |
|
8
Coursera
COUR
$1.59B
| $72.6M | 4.57% |
12,867,769
| – | – |
|
9
Aurinia Pharmaceuticals
AUPH
$2.14B
| $67.4M | 4.24% |
3,969,834
| – | – |
|
10
CRISPR Therapeutics
CRSP
$5.46B
| $57.7M | 3.64% |
1,058,570
| – | – |
|
11
Oric Pharmaceuticals
ORIC
$1.32B
| $44.6M | 2.81% |
4,118,621
| – | – |
|
12
Phathom Pharmaceuticals
PHAT
$732M
| $21.3M | 1.34% |
1,960,169
| – | – |
|
13
Korro Bio
KRRO
$171M
| $17.1M | 1.08% |
1,297,893
| – | – |
|
14
X4 Pharmaceuticals
XFOR
$401M
| $15.1M | 0.95% |
3,233,743
| – | – |
|
15
Champions Oncology
CSBR
$73.5M
| $10.6M | 0.66% |
1,713,720
| – | – |
|
16
Nkarta
NKTX
$200M
| $10.1M | 0.64% |
3,568,781
| – | – |
|
|
17
CVRx
CVRX
$80.2M
| $10M | 0.63% |
1,954,440
-71,643
| -4% | -$462K |
|
18
Black Diamond Therapeutics
BDTX
$121M
| $8.23M | 0.52% |
4,448,757
| – | – |
|
|
19
Karyopharm Therapeutics
KPTI
$40.1M
| $5.64M | 0.35% |
+576,780
| New | +$5M |
|
|
IVA
20
Inventiva
IVA
$1.14B
| $5.53M | 0.35% |
1,462,586
| – | – |
|
|
LONA
21
LeonaBio Inc
LONA
$72.5M
| $4.27M | 0.27% |
464,398
| – | – |
|
22
Senti Biosciences Holdings
SNTI
$10.6M
| $4.15M | 0.26% |
3,775,615
| – | – |
|
23
Marker Therapeutics
MRKR
$20.7M
| $2.39M | 0.15% |
1,625,678
| – | – |
|
|
OKUR
24
OnKure Therapeutics
OKUR
$144M
| $2.18M | 0.14% |
478,548
| – | – |
|
|
IMA
25
ImageneBio Inc
IMA
$55.5M
| $295K | 0.02% |
50,005
| – | – |
|
Similar funds
ADL
CCP
ACM
SW
GCP
W
PIS
FWP
NEA Management Company's Q2 2026 Portfolio in Review
As of Q2 2026, NEA Management Company held 27 positions worth $1.59B, down 9.7% from $1.76B the previous quarter. Its ten largest holdings account for 90% of the portfolio.
NEA Management Company withdrew a net $411M in Q2 2026, closing 1 position and reducing 2 holdings. Its most notable exit was Arcellx, an estimated $350M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Consumer Staples.
Against the trend, NEA Management Company opened a new position in Karyopharm Therapeutics worth $5.64M.
- NEA Management Company's largest Q2 2026 buy was Karyopharm Therapeutics: 576,780 shares worth $5.64M.
- NEA Management Company's biggest Q2 2026 reduction was Celcuity, cutting an estimated $66.3M.
- NEA Management Company fully exited Arcellx in Q2 2026, selling an estimated $350M.
- NEA Management Company's ten largest holdings make up 90% of its $1.59B portfolio in Q2 2026.
- NEA Management Company opened 1 new position and closed 1 in Q2 2026.
- NEA Management Company's portfolio value fell 9.7% quarter-over-quarter to $1.59B.
Based on NEA Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.